Canada markets closed

FSD Pharma Inc. (HUGE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5400+0.0200 (+1.32%)
At close: 4:00PM EDT
1.5700 +0.03 (1.95%)
After hours: 07:39PM EDT

FSD Pharma Inc.

First Canadian Place
Suite 3400 100 King Street West
Toronto, ON M5X 1A4
416 854 8884

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Mr. Zeeshan SaeedFounder, Pres & Exec. Co-Chairman224.6kN/A1972
Mr. Anthony John DurkaczFounder, Interim CEO & Exec. Co-ChairmanN/AN/A1976
Dr. Sara May Ph.D.Sr. VP152.8kN/AN/A
Dr. Edward J. Brennan Jr., F.A.C.S., FACS, M.D.Chief Medical Officer461.33kN/AN/A
Mr. Nathan Coyle CPACFO & Corp. ControllerN/AN/AN/A
Ms. Maryann AdessoCorp. Sec.N/AN/AN/A
Randell MackPres of FSD BioSciencesN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.

Corporate Governance

FSD Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.